NASDAQ:TXMD

TherapeuticsMD (TXMD) Stock Forecast, Price & News

$3.02

+0.08 (+2.72%)

(As of 09/29/2023 ET)

Compare

Today's Range: $2.86
▼
$3.02
50-Day Range: $2.89
▼
$4.26
52-Week Range: $2.68
▼
$7.53

Volume: 12,456 shs
Average Volume: 17,996 shs
Market Capitalization: $31.92 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

TherapeuticsMD MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Bearish
3.78% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.29
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.75) to $0.15 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.98 out of 5 stars

Medical Sector

958th out of 972 stocks

Pharmaceutical Preparations Industry

443rd out of 449 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for TherapeuticsMD.

1.0

Short Interest

Percentage of Shares Shorted
3.78% of the float of TherapeuticsMD has been sold short.
Short Interest Ratio / Days to Cover
TherapeuticsMD has a short interest ratio ("days to cover") of 18.2, which indicates bearish sentiment.
Change versus previous month
Short interest in TherapeuticsMD has recently increased by 21.26%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
TherapeuticsMD does not currently pay a dividend.
Dividend Growth
TherapeuticsMD does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TXMD.

2.4

News and Social Media Coverage

News Sentiment
TherapeuticsMD has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for TherapeuticsMD this week, compared to 0 articles on an average week.
Search Interest
5 people have searched for TXMD on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added TherapeuticsMD to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, TherapeuticsMD insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.20% of the stock of TherapeuticsMD is held by insiders.
Percentage Held by Institutions
Only 28.68% of the stock of TherapeuticsMD is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for TherapeuticsMD are expected to grow in the coming year, from ($0.75) to $0.15 per share.
Price to Book Value per Share Ratio
TherapeuticsMD has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About TherapeuticsMD (NASDAQ:TXMD) Stock

TherapeuticsMD, Inc. operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

TXMD Price History

30 days | 90 days | 365 days | Advanced Chart

TXMD Stock News Headlines

September 28, 2023 | americanbankingnews.com

StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD)

September 22, 2023 | americanbankingnews.com

TherapeuticsMD (NASDAQ:TXMD) Now Covered by StockNews.com

October 1, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

September 20, 2023 | marketwatch.com

TherapeuticsMD Inc. stock falls Wednesday, underperforms market

August 15, 2023 | marketwatch.com

TherapeuticsMD Inc. stock outperforms market despite losses on the day

August 14, 2023 | finance.yahoo.com

TherapeuticsMD Announces Second Quarter 2023 Financial Results

August 9, 2023 | finance.yahoo.com

Micron Biomedical Appoints Brian Bernick, MD as Chairman of Its Board of Directors

July 5, 2023 | marketwatch.com

TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors

October 1, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

July 4, 2023 | thestreet.com

TherapeuticsMD Rejected by FDA, Delay Could Be Fatal

May 23, 2023 | seekingalpha.com

TherapeuticsMD: From Fallen And Forgotten To Cash Cow

May 15, 2023 | finance.yahoo.com

TherapeuticsMD Announces First Quarter 2023 Financial Results

May 10, 2023 | marketwatch.com

TherapeuticsMD Inc. stock falls Tuesday, underperforms market

May 10, 2023 | marketwatch.com

TherapeuticsMD Inc. stock rises Wednesday, still underperforms market

May 3, 2023 | marketwatch.com

TherapeuticsMD Inc. stock falls Monday, underperforms market

April 30, 2023 | marketwatch.com

TherapeuticsMD Inc. stock underperforms Friday when compared to competitors

April 23, 2023 | marketwatch.com

TherapeuticsMD Inc. stock outperforms market on strong trading day

April 14, 2023 | msn.com

All You Need to Know About TherapeuticsMD (TXMD) Rating Upgrade to Buy

April 7, 2023 | finance.yahoo.com

TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition

March 13, 2023 | marketwatch.com

TherapeuticsMD Inc. stock underperforms Monday when compared to competitors

January 5, 2023 | bizjournals.com

TheraputicsMD sells products rights for $153 million

January 3, 2023 | finance.yahoo.com

TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma

December 26, 2022 | reuters.com

TXMD.A - TherapeuticsMD Inc | Stock Price & Latest News | Reuters

December 19, 2022 | bizjournals.com

Technology & Innovation Roundup: Company will cut 212 employees after failed buyout

December 16, 2022 | marketwatch.com

TherapeuticsMD Inc. stock falls Thursday, underperforms market

December 15, 2022 | marketwatch.com

TherapeuticsMD Inc. stock rises Wednesday, outperforms market

December 4, 2022 | finance.yahoo.com

TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma

See More Headlines

Receive TXMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TherapeuticsMD and its competitors with MarketBeat's FREE daily newsletter.

TXMD Company Calendar

Last Earnings: 8/14/2023
Today: 10/01/2023
Next Earnings (Estimated): 11/13/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TXMD
Previous Symbol: NYSEMKT:TXMD
CUSIP: N/A
CIK: 25743
Web: www.therapeuticsmd.com
Phone: (561) 961-1900
Fax: 561-431-3389
Employees: 1
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $112 million
Net Margins: 61.23%
Pretax Margin: 41.70%
Return on Equity: 232.35%
Return on Assets: 34.47%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.37
Quick Ratio: 1.37

Sales & Book Value

Annual Sales: $69.96 million
Price / Sales: 0.46
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.73 per share
Price / Book: 0.81

Miscellaneous

Outstanding Shares: 10,570,000
Free Float: 10,448,000
Market Cap: $31.92 million
Optionable: Optionable
Beta: 1.14

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Governor Thomas G. Thompson (Age 81)
Exec. Chairman
Comp: $150k

Mr. Marlan D. Walker J.D. (Age 47)
Chief Exec. Officer
Comp: $1.13M

Mr. Robert G. Finizio (Age 52)
Co-Founder
Comp: $7.51k

Mr. Michael C. Donegan (Age 55)
Interim CFO & Chief Accounting Officer
Comp: $712.59k

Ms. Daniella Silva (Age 37)
Chief Compliance Officer

Mr. Benjamin Foulk (Age 53)
VP of HR

Mr. Bharat Warrier (Age 45)
Chief Manufacturing Officer

Mr. Douglas Steelman
VP of Market Access

Ms. Dedra Lyden
VP of Strategic Partnerships & Initiatives

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TXMD Stock - Frequently Asked Questions

Should I buy or sell TherapeuticsMD stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" TXMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TXMD, but not buy additional shares or sell existing shares.
View TXMD analyst ratings or view top-rated stocks.
How have TXMD shares performed in 2023?: TherapeuticsMD's stock was trading at $5.59 on January 1st, 2023. Since then, TXMD stock has decreased by 46.0% and is now trading at $3.02.
View the best growth stocks for 2023 here.
Are investors shorting TherapeuticsMD?: TherapeuticsMD saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 369,000 shares, an increase of 21.3% from the August 31st total of 304,300 shares. Based on an average daily trading volume, of 20,300 shares, the days-to-cover ratio is currently 18.2 days. Approximately 3.8% of the shares of the stock are sold short.
View TherapeuticsMD's Short Interest.
When is TherapeuticsMD's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our TXMD earnings forecast.
How were TherapeuticsMD's earnings last quarter?: TherapeuticsMD, Inc. (NASDAQ:TXMD) issued its earnings results on Monday, August, 14th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by $0.17. The company had revenue of $0.44 million for the quarter. TherapeuticsMD had a net margin of 61.23% and a trailing twelve-month return on equity of 232.35%.
When did TherapeuticsMD's stock split?: TherapeuticsMD shares reverse split on the morning of Monday, May 9th 2022. The 1-50 reverse split was announced on Monday, May 9th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of TherapeuticsMD own?: Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include OPKO Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Cleveland-Cliffs (CLF), Novavax (NVAX) and Micron Technology (MU).
What is TherapeuticsMD's stock symbol?: TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."
How do I buy shares of TherapeuticsMD?: Shares of TXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is TherapeuticsMD's stock price today?: One share of TXMD stock can currently be purchased for approximately $3.02.
How much money does TherapeuticsMD make?: TherapeuticsMD (NASDAQ:TXMD) has a market capitalization of $31.92 million and generates $69.96 million in revenue each year.
How can I contact TherapeuticsMD?: TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The official website for the company is www.therapeuticsmd.com. The company can be reached via phone at (561) 961-1900, via email at shareholder@broadridge.com, or via fax at 561-431-3389.

This page (NASDAQ:TXMD) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial